Unnamed: 0,title,date,stock,sentiment
985150.0,"Cantor Fitzgerald Maintains Neutral on Puma Biotechnology, Raises Price Target to $16",2020-05-20 07:24:00-04:00,PBYI,neutral
985151.0,Puma Biotechnology shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.,2020-05-08 10:46:00-04:00,PBYI,positive
985152.0,"Puma Biotechnology Q1 Adj. EPS $(0.200) Beats $(0.730) Estimate, Sales $48.600M Beat $47.060M Estimate",2020-05-07 16:13:00-04:00,PBYI,neutral
985153.0,Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval In Mainland China For NERLYNX For Extended Adjuvant Treatment Of Early Stage HER2-Positive Breast Cancer,2020-05-07 08:48:00-04:00,PBYI,negative
985154.0,"UPDATE: Puma Biotech Says Will Receive Upfront, Milestone Payments Of Up To $6M",2020-04-30 16:35:00-04:00,PBYI,neutral
985155.0,Puma Biotech Reports Exclusive License Deal With Bixink Therapeutics For Commercialization Of NERLYNX (Neratinib) In South Korea,2020-04-30 16:35:00-04:00,PBYI,positive
985156.0,"Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.",2020-04-21 11:35:00-04:00,PBYI,negative
985157.0,Puma Biotech Reports FDA Approval Of Supplemental New Drug Application For Neratinib To Treat HER2-Positive Metastatic Breast Cancer,2020-02-26 08:05:00-05:00,PBYI,positive
985158.0,Puma Biotechnology shares are trading lower after the company reported worse-than-expected Q4 sales results.,2020-02-21 09:14:00-05:00,PBYI,neutral
985159.0,"Puma Biotechnology Q4 EPS $0.01, Sales $58.7M Miss $59.96M Estimate",2020-02-20 16:10:00-05:00,PBYI,negative
985160.0,Puma Biotechnology shares are trading higher following yesterday's presentation at the JP Morgan Healthcare Conference.,2020-01-16 11:24:00-05:00,PBYI,positive
985161.0,"Puma Biotechnology shares are trading higher ahead of the company's Wednesday presentation at the JP Morgan Healthcare Conference. At the conference, the company will provide an update and highlight preliminary NERLYNX sales for Q4.",2020-01-14 14:13:00-05:00,PBYI,positive
985162.0,Puma Biotechnology shares are trading lower after the company presented interim results for its Phase 2 clinical trial of Neratinib.,2019-12-16 11:43:00-05:00,PBYI,neutral
985163.0,Puma Biotechnologies shares are trading higher on continued momentum after the company reported data on its Nerlynx for breast cancer patients.,2019-12-13 09:27:00-05:00,PBYI,negative
985164.0,"Puma Biotech Shares Relatively Quiet Following Press Release Highlighting Collaborators At The Institute Of Cancer Research, London Presented Results From Cohort Of Patients In plasmaMATCH Trial Treated With Co.'s Neratinib At SABCS",2019-12-12 12:45:00-05:00,PBYI,negative
985165.0,Puma Biotechnology shares are trading higher. Not seeing any news to justify the price action.,2019-12-10 11:47:00-05:00,PBYI,positive
985166.0,"H.C. Wainwright Initiates Coverage On Puma Biotechnology with Buy Rating, Announces $15 Price Target",2019-12-06 07:29:00-05:00,PBYI,neutral
985167.0,Puma Biotechnology shares are trading lower. Not seeing any news to justify the price action. NOTE: The stock has dropped approximately 25% over the past 3 trading sessions.,2019-12-05 11:08:00-05:00,PBYI,neutral
985168.0,Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval In Singapore For NERLYNX For Extended Adjuvant Treatment Of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer,2019-12-02 16:32:00-05:00,PBYI,positive
985169.0,"Puma Biotechnology shares are trading higher after the company extended its commercialization agreement with Pierre Fabre for NERLYNX to the Middle East, South Africa, Sudan, and Turkey.",2019-12-02 11:55:00-05:00,PBYI,positive
985170.0,"Puma Biotechnology Extends its Commercialization Agreement with Pierre Fabre for NERLYNX to the Middle East, South Africa, Sudan and Turkey",2019-12-02 08:07:00-05:00,PBYI,positive
985171.0,Puma Biotechnology shares are trading lower on seemingly no company-specific news.,2019-11-14 13:58:00-05:00,PBYI,negative
985172.0,Puma Biotechnology shares are trading higher on continued momentum after the company reported better-than-expected Q3 EPS results.,2019-11-08 11:10:00-05:00,PBYI,positive
985173.0,"Puma Biotechnology Q3 EPS $(0.44) Beats $(0.71) Estimate, Sales $56.4M Miss $60.4M Estimate",2019-11-06 16:16:00-05:00,PBYI,negative
985174.0,"Puma Biotech Reports Its Licensing Partner, CANbridge Pharma, Receives Registration Approval In Hong Kong For NERLYNX",2019-11-05 16:44:00-05:00,PBYI,positive
985175.0,"UPDATE: Goldman On Puma Biotechnology Also Notes 'We believe that even if tucatinib is not differentiated on efficacy, it may garner more market share on greater tolerability based on mCRC data shown at ESMO'",2019-10-08 10:52:00-04:00,PBYI,positive
985176.0,"UPDATE: Goldman Downgrades Puma Biotechnology To Sell, Lowers Target To $8 As Firm Notes 'we think the headline risk from upcoming competitive data at YE2019 from SGEN's tucatinib (link) is underappreciated and creates a challenging set up'",2019-10-08 10:51:00-04:00,PBYI,positive
985177.0,Puma Biotechnology shares are trading lower after Goldman Sachs downgraded the company's stock from Neutral to Sell and lowered the price target from $24 to $8.,2019-10-08 09:30:00-04:00,PBYI,negative
985178.0,"Goldman Sachs Downgrades Puma Biotechnology to Sell, Lowers Price Target to $8",2019-10-08 06:54:00-04:00,PBYI,negative
985179.0,Puma Biotech Reports FDA Approved Labeling Supplement For Co.'s NERLYNX For Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,2019-10-02 16:17:00-04:00,PBYI,negative
985180.0,Puma Biotechnology Announces FDA Acceptance Of Supplemental New Drug Application For Neratinib To Treat HER2-Positive Metastatic Breast Cancer,2019-09-11 08:09:00-04:00,PBYI,positive
985181.0,"Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization For NERLYNX For Extended Adjuvant Treatment Of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer",2019-09-04 16:11:00-04:00,PBYI,negative
985182.0,Puma Biotech shares are trading higher after the FDA granted Orphan Drug Destination to NERLYNX for the treatment of breast cancer patients with brain metastases.,2019-09-03 16:25:00-04:00,PBYI,negative
985183.0,Puma Biotech Reports FDA Granted Orphan Drug Designation For Co.'s NERLYNX For Treatment Of Breast Cancer Patients With Brain Metastases,2019-09-03 16:22:00-04:00,PBYI,negative
985184.0,"Barclays Maintains Underweight on Puma Biotechnology, Lowers Price Target to $9",2019-08-09 09:00:00-04:00,PBYI,negative
985185.0,Puma Biotechnology shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-08-09 08:31:00-04:00,PBYI,positive
985186.0,Puma Biotechnology shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.,2019-08-08 16:28:00-04:00,PBYI,positive
985187.0,"Puma Biotechnology Q2 EPS $(0.97) Beats $(1) Estimate, Sales $53.9M Beat $52.98M Estimate",2019-08-08 16:27:00-04:00,PBYI,neutral
985188.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Fri., July 26, 2019",2019-07-26 14:21:00-04:00,PBYI,positive
985189.0,Puma Biotech Highlights Its Licensing Partner Knight Therapeutics Received Regulatory Approval From Health Canada Related To Commericalization Of NERLYNX For HER2-Positive Early-Stage Breast Cancer,2019-07-16 16:37:00-04:00,PBYI,negative
985190.0,Puma Biotech Highlights Presentation Of Interim Results From Biliary Tract Cohort At World Congress On Gastrointestinal Cancer,2019-07-03 12:10:00-04:00,PBYI,negative
985191.0,Puma Biotechnology Submits a Supplemental New Drug Application to the US FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer,2019-07-01 08:06:00-04:00,PBYI,negative
985192.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Fri., June 14, 2019",2019-06-14 13:11:00-04:00,PBYI,positive
985193.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Radar Tool For Thur., June 13, 2019",2019-06-13 14:55:00-04:00,PBYI,positive
985194.0,Puma Biotechnology Highlights Presentation Of Results From Phase III NALA Trial Of Neratinib In Patients With HER2-Positive Metastatic Breast Cancer At ASCO 2019 Annual Meeting,2019-06-04 11:12:00-04:00,PBYI,negative
985195.0,Puma Biotechnology shares are trading lower after the company reported its Q1 Nerlynx sales declined from the previous quarter due to patients discontinuing treatment. Cantor Fitzgerald downgraded the stock from Overweight to Neutral.,2019-05-10 09:53:00-04:00,PBYI,negative
985196.0,"Citi Downgrades Puma Biotechnology Inc - Common Stock to Neutral, Announces $24 Price Target",2019-05-10 08:34:00-04:00,PBYI,neutral
985197.0,"Cantor Fitzgerald Downgrades Puma Biotechnology Inc - Common Stock to Neutral, Lowers Price Target to $20",2019-05-10 06:55:00-04:00,PBYI,negative
985198.0,Puma Biotechnology shares are trading lower after the company reported Q1 Nerlynx sales decline from last quarter due to an increase in patients discontinuing treatment.,2019-05-09 17:09:00-04:00,PBYI,positive
985199.0,Puma Biotechnology Reports Q1 Nerlynx Sales Declined From Last Quarter Due To An Increase In Patients Discontinuing Treatment,2019-05-09 17:06:00-04:00,PBYI,positive
985200.0,"Puma Biotechnology Q1 EPS $(0.26) Beats $(0.68) Estimate, Sales $99.1M Beat $67.25M Estimate",2019-05-09 17:04:00-04:00,PBYI,neutral
985201.0,Alterity Therapeutics Highlights Initial Data Presented At American Academy of Neurology Annual Meeting,2019-05-06 08:13:00-04:00,PBYI,neutral
985202.0,"Puma Biotech Reports Expansion Of Cohorts In Phase II SUMMIT Trial Of Neratinib In Cancer Patients With Tumors With Activating EGFR, HER2 Mutations",2019-04-04 08:30:00-04:00,PBYI,negative
985203.0,Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX in Europe,2019-04-01 08:01:00-04:00,PBYI,positive
985204.0,Puma Biotech Highlights Publication Of 12 Abstracts On Neratinib For AACR Annual Meeting 2019,2019-03-28 08:34:00-04:00,PBYI,neutral
985205.0,From Earlier: Puma Biotechnology's Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval To Commercialize NERLYNX For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer,2019-03-18 15:52:00-04:00,PBYI,negative
985206.0,Puma Biotechnology shares are trading higher after the company reported better-than-expected Q4 EPS and sales estimates; the company also reported a 204% year-over-year increase in sales of its NERLYNX breast cancer treatment.,2019-03-01 07:54:00-05:00,PBYI,negative
985207.0,"Puma Biotechnology Q4 EPS $(0.32) Beats $(0.77) Estimate, Sales $71.1M Beat $53.65M Estimate",2019-02-28 16:57:00-05:00,PBYI,neutral
985208.0,"Centers For Medicaid, Medicare Has Proposed Coverage With Evidence Development For CAR-T Therapy, Decision Would Provide Nationwide Consistency In CMS Coverage",2019-02-15 09:01:00-05:00,PBYI,neutral
985209.0,Leerink Swann Initiates Coverage On Puma Biotechnology with Market Perform Rating,2019-01-17 08:14:00-05:00,PBYI,neutral
985210.0,Puma Biotechnology Enters Into An Exclusive License Agreement With Knight Therapeutics That Grants Knight The Exclusive Right To commercialize NERLYNX (neratinib) In Canada,2019-01-11 08:05:00-05:00,PBYI,positive
985211.0,Guggenheim Downgrades Puma Biotechnology to Neutral,2019-01-03 08:35:00-05:00,PBYI,neutral
985212.0,Puma Biotechnology shares are trading higher after the company reported favorable results from its Phase III NALA trial of Neratinib in breast cancer patients.,2018-12-17 16:55:00-05:00,PBYI,neutral
985213.0,Puma Biotechnology Says top Line Results From Phase III NALA Trial Of Neratinib In Breast Cancer Patients Resulted In Statistically Significant Improvement In Centrally Confirmed Progression Free Survival; Safety Profile Consistent With Previous Trials,2018-12-17 16:07:00-05:00,PBYI,positive
985214.0,Puma Biotech Offers Results Of Patient-Reported Outcomes In Phase II CONTROL Trial Of Neratinib In Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer At San Antonio Breast Cancer Symposium,2018-12-06 08:08:00-05:00,PBYI,negative
985215.0,"Goldman Sachs Upgrades Puma Biotechnology to Neutral, Lowers Price Target to $28",2018-11-19 06:13:00-05:00,PBYI,negative
985216.0,"JP Morgan Maintains Underweight on Puma Biotechnology, Lowers Price Target to $23",2018-11-02 13:10:00-04:00,PBYI,positive
985217.0,JP Morgan Earlier On Puma Biotech: Sees Shares Underperforming Firm's Coverage Universe Until Evidence Of Sustained Commercial Momentum Is Apparent,2018-11-02 12:52:00-04:00,PBYI,positive
985218.0,"Cantor Fitzgerald Maintains Overweight on Puma Biotechnology, Lowers Price Target to $50",2018-11-02 10:36:00-04:00,PBYI,negative
985219.0,"Barclays Downgrades Puma Biotechnology to Underweight, Lowers Price Target to $29",2018-11-02 06:52:00-04:00,PBYI,negative
985220.0,"JP Morgan Downgrades Puma Biotechnology to Underweight, Lowers Price Target to $23",2018-11-02 06:51:00-04:00,PBYI,positive
985221.0,Puma Biotechnology shares are trading lower after the company's Nerlynx sales were lower than expected.,2018-11-01 18:01:00-04:00,PBYI,negative
985222.0,"Puma Biotechnology Q3 Adj. EPS $0.17 Beats $(0.97) Estimate, Sales $52.6M Miss $57.94M Estimate",2018-11-01 16:22:00-04:00,PBYI,negative
985223.0,"Stocks Which Set New 52-Week Low Yesterday, October 31st",2018-11-01 10:37:00-04:00,PBYI,negative
985224.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,PBYI,negative
985225.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,PBYI,negative
985226.0,Celcuity Announces Clinical Trial Collaboration With Puma Biotechnology And West Cancer Center,2018-10-16 17:51:00-04:00,PBYI,negative
985227.0,Puma Biotechnology's Licensing Partner CANbridge Pharmaceutical Submits New Drug Application For NERLYNX (neratinib) In China,2018-10-02 08:30:00-04:00,PBYI,neutral
985228.0,"Cantor Fitzgerald Initiates Coverage On Puma Biotechnology with Overweight Rating, Announces $75 Price Target",2018-10-01 08:19:00-04:00,PBYI,negative
985229.0,"Citigroup Maintains Buy on Puma Biotechnology, Lowers Price Target to $151",2018-09-18 08:07:00-04:00,PBYI,negative
985230.0,"Goldman Sachs Initiates Coverage On Puma Biotechnology with Sell Rating, Announces $42 Price Target",2018-09-17 08:24:00-04:00,PBYI,neutral
985231.0,European Commission Grants Marketing Authorisation To Puma Biotechnology's NERLYNX For Extended Adjuvant Treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer,2018-09-04 08:16:00-04:00,PBYI,neutral
985232.0,Puma Biotechnology shares are up 11.6% premarket after the company beat Q2 earnings estimates.,2018-08-10 09:08:00-04:00,PBYI,positive
985233.0,"Puma Biotechnology Q2 EPS $(0.59) Beats $(1.26) Estimate, Sales $50.8M Beat $45.67M Estimate",2018-08-09 16:37:00-04:00,PBYI,neutral
985234.0,"Stocks Which Set New 52-Week Low Yesterday, August 8th",2018-08-09 11:10:00-04:00,PBYI,negative
985235.0,"Stocks Which Set New 52-Week Low Yesterday, August 7th",2018-08-08 11:06:00-04:00,PBYI,negative
985236.0,"Stocks Which Set New 52-Week Low Yesterday, July 31",2018-08-01 12:16:00-04:00,PBYI,negative
985237.0,Puma Biotechnology Files New Drug Submission For NERLYNX For Breast Cancer In Canada,2018-07-31 08:32:00-04:00,PBYI,negative
985238.0,Puma Biotechnology Announces Collaboration With Strata Oncology To Accelerate Enrollment In Phase II SUMMIT trial Of PB272; SUMMIT Trial Evaluates Safety And Efficacy Of Neratinib In Patients With Solid Tumors With Mutations,2018-07-17 16:17:00-04:00,PBYI,positive
985239.0,Puma Biotech Reports Received Positive CHMP Opinion Related To Approval Of NERLYNX For Extended Adjuvant Treatment Oh HER2-Positive Early Stage Breast Cancer,2018-06-29 07:32:00-04:00,PBYI,positive
985240.0,"Citigroup Maintains Buy on Puma Biotechnology, Raises Price Target to $164",2018-06-28 07:39:00-04:00,PBYI,neutral
985241.0,"Puma Biotech Shares Resume Trade, Up 31.7%",2018-06-26 09:16:00-04:00,PBYI,positive
985242.0,Puma Biotech Shares To Resume Trade At 9:15 a.m. EDT,2018-06-26 08:56:00-04:00,PBYI,positive
985243.0,Puma Biotech Reports Results Of CHMP Reexamination Of MAA For Neratinib For Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer: Recommended Approval,2018-06-26 08:52:00-04:00,PBYI,negative
985244.0,Puma Biotech Shares Halted News Pending,2018-06-26 08:34:00-04:00,PBYI,positive
985245.0,Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies,2018-06-18 08:30:00-04:00,PBYI,negative
985246.0,Puma Biotechnology Option Alert: Jul 20 $60 Calls at the Ask: 5000 @ $1.7 vs 1402 OI; Earnings 8/8 After Close [est] Ref=$52.3,2018-06-14 12:32:00-04:00,PBYI,positive
985247.0,"Jefferies 2018 Global Healthcare Conference Continues Today, Presenters Include: bluebird bio, GlycoMimetics, Five Prime Therapeutics, GTx, ImmunoGen, Puma Biotech, and Deciphera Pharma",2018-06-07 07:13:00-04:00,PBYI,neutral
985248.0,"Puma Biotech Shares Down 17% For Session; Hearing Citi Issued Mid-Day Defense On Name, Called Selloff Overdone",2018-05-10 12:30:00-04:00,PBYI,positive
985249.0,"Puma Biotechnology Q1 Adj. EPS $0.03 Beats $(1) Estimate, Sales $66.5M Beat $58.5M Estimate",2018-05-09 17:23:00-04:00,PBYI,neutral
985250.0,Barclays Downgrades Puma Biotechnology to Equal-Weight,2018-04-12 06:39:00-04:00,PBYI,neutral
985251.0,"Puma Biotech, Pint Pharma Report Exclusive Licensing Deal To Commercialize Neratinib In Latin America",2018-04-03 08:45:00-04:00,PBYI,positive
985252.0,Puma Biotechnology Announces that NERLYNX Has Been Included as a Treatment Option in the National Comprehensive Cancer Network,2018-04-02 08:49:00-04:00,PBYI,negative
985253.0,"Barclays Maintains Overweight on Puma Biotechnology, Lowers Price Target to $90.00",2018-03-02 12:17:00-05:00,PBYI,negative
985254.0,"Puma Biotechnology Reports Q4 Adj. EPS $(1.03) vs $(1.98) Est., Sales $20.1M vs $20.0M Est.",2018-03-01 16:12:00-05:00,PBYI,neutral
985255.0,Puma Biotech Shares Quiet Premarket Following EMA Recommendation Against Approval Of Co.'s Neratin,2018-02-23 07:22:00-05:00,PBYI,positive
985256.0,"Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma",2018-02-14 07:06:00-05:00,PBYI,neutral
985257.0,"Puma Biotechnology, CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX In China; Puma To Receive $30M Upfront And $40M In Potential Milestone Payments",2018-02-01 16:22:00-05:00,PBYI,positive
985258.0,"Puma Biotech Reports Publication Of Results From Phase II SUMMIT Basket Trial On Neratinib In HER2, HER3 Mutant Cancers",2018-01-31 13:17:00-05:00,PBYI,neutral
985259.0,Puma Biotech Shares Ticking Modestly Lower As Traders Circulating FDA.gov Alert 'FDA limits packaging for anti-diarrhea medicine Loperamide (Imodium) to encourage safe use',2018-01-30 10:58:00-05:00,PBYI,positive
985260.0,"Puma Biotechnology, Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX",2018-01-30 08:15:00-05:00,PBYI,positive
985261.0,"Puma Biotech Shares Down 26.73% On Earlier Cowen Downgrade, Subsequent STAT News' Adam F Twitter Mention",2018-01-24 11:22:00-05:00,PBYI,positive
985262.0,Cowen & Co. Downgrades Puma Biotechnology to Market Perform,2018-01-24 07:06:00-05:00,PBYI,neutral
985263.0,UPDATE: Puma Says Negative Trend Vote Means 'additional steps would need to be taken to gain marketing approval in Europe',2018-01-23 16:25:00-05:00,PBYI,positive
985264.0,Puma Biotech Reports EMA's CHMP Communicated Negative Trend Vote After Meeting To Discuss MAA For Neratinib,2018-01-23 16:21:00-05:00,PBYI,negative
985265.0,"Puma Biotech 8-K Shows, Based On CHMP SAG Opinion, Co. 'intends to modify the SmPC...in its MAA for neratinib to further refine the intended population to patients at a high risk of disease recurrence'",2018-01-11 16:11:00-05:00,PBYI,negative
985266.0,"Adam Feuerstein Tweets: $PBYI is not presenting at #JPM18 but before your M&A hearts get all a-flutter, it's because they're in Europe for an EMA meeting related to the Nerlynx review.",2018-01-05 11:31:00-05:00,PBYI,neutral
985267.0,"Puma Biotechnology Shares Up 3.18%; Bank Of America Out Defending, Says Stock Selloff On FDA's FAERS Death Reports Overdone, Says Unconcerned About Safety Of Nerlynx Treatment And Maintains Buy Rating",2018-01-03 10:45:00-05:00,PBYI,negative
985268.0,Puma Biotech Reports EMA Requested Scientific Advisory Group On Oncology Provide Opinion On Clinical Aspects Of MAA For Neratinib At Jan. 11 Meeting,2017-12-13 16:22:00-05:00,PBYI,neutral
985269.0,"Puma Biotech, Daiichi Sankyo Report Research Collaboration With Major Cancer Center In HER2-Mutated Cancer",2017-12-12 16:19:00-05:00,PBYI,negative
985270.0,Puma Biotechnology Announces Patent Claims for Extended Adjuvant Treatment Upheld,2017-12-11 08:47:00-05:00,PBYI,neutral
985271.0,Puma Biotech Will Present Updated Interim Results From Phase II CONTROL Trial Of Neratinib Dec. 7 6pm ET At San Antonio Breast Cancer Symposium,2017-12-06 15:15:00-05:00,PBYI,negative
985272.0,"UPDATE: Puma Says Will Receive Upfront, Milestone Payments Of Up to $4.5M Throughout Term Of NERLYNX Commercialize Deal",2017-11-22 09:18:00-05:00,PBYI,neutral
985273.0,"Puma Biotech, Specialised Therapeutics Asia Report Entered Into Exclusive Licensing Deal To Commercialize NERLYNX In Australia, New Zealand, South East Asia",2017-11-22 09:17:00-05:00,PBYI,positive
985274.0,"Stifel 2017 Healthcare Conference Concludes Today, Presenters Include: Eleven Biotherapeutics, Clovis, Puma Biotechnology, Synlogic, KalVista Pharmaceuticals, Dicerna Pharmaceuticals, GTx, and Acorda Therapeutics",2017-11-15 08:59:00-05:00,PBYI,neutral
985275.0,"Barclays Maintains Overweight on Puma Biotechnology, Raises Price Target to $122.00",2017-11-10 12:20:00-05:00,PBYI,negative
985276.0,"Credit Suisse Maintains Outperform on Puma Biotechnology, Raises Price Target to $142.00",2017-11-10 10:58:00-05:00,PBYI,positive
985277.0,"Puma Biotechnology Reports Q3 Adj. EPS $(1.36) vs $(2.49) Est., Sales $6.1M vs $3.74M Est.",2017-11-09 16:09:00-05:00,PBYI,neutral
985278.0,"Credit Suisse Healthcare Conference Continues Today, Presenters Include: Walgreens, Vertex Pharmaceuticals, Laboratory Corp, Puma Biotech, Anthem, Alexion Pharma, Celgene, and Gilead",2017-11-07 09:06:00-05:00,PBYI,positive
985279.0,Puma Biotechnology Secures $100M Term Loan from Silicon Valley Bank and Oxford Finance,2017-11-02 16:20:00-04:00,PBYI,positive
985280.0,"Citi Raises Target On Puma Biotech To $156, Reiterates Co. As Acquisition Target",2017-10-05 07:57:00-04:00,PBYI,neutral
985281.0,"Cantor Fitzgerald Global Healthcare Conference Continues Today, Presenters Include:  Innoviva, Puma Biotech, Magellan Health, TherapeuticsMD, Zoetis, Aurinia Pharma and Celgene",2017-09-26 08:36:00-04:00,PBYI,neutral
985282.0,"European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5",2017-09-08 09:15:00-04:00,PBYI,neutral
985283.0,Puma Biotech Reports Presentation Of 5-Year Analysis Of Phase III ExteNET Trial In Extended Adjuvant HER2-Positive Breast Cancer: Showed 'Continued Benefit from Neratinib after 5 years',2017-09-08 09:03:00-04:00,PBYI,negative
985284.0,"Barclays Initiates Coverage On Puma Biotechnology with Overweight Rating, Announces $103.00 Price Target",2017-09-07 07:29:00-04:00,PBYI,negative
985285.0,"Citi Biotech Conference Begins Today, Presenters Include: Gilead, Ligand, Puma Biotech, and Bioverativ",2017-09-06 09:13:00-04:00,PBYI,neutral
985286.0,Puma Biotech Reports Q2 Adj. EPS $(1.38) vs $(2.04) Est.,2017-08-09 16:21:00-04:00,PBYI,neutral
985287.0,Puma Biotech Reports Received Day-180 List Of Outstanding Issues From Committee For Medicinal Products For Human Use,2017-08-02 17:28:00-04:00,PBYI,positive
985288.0,"Leerink Out Defending Puma Biotechnology, Says Shares Are Underperforming On Company News That Nerlyx Is Now Commercially Available By Prescription In U.S.; Believes Weakness In Shares Provides Buying Opportunity And Reiterates Outperform Rating",2017-08-01 12:11:00-04:00,PBYI,positive
985289.0,Puma Biotech Announces NERLYNX Now Commercially Available,2017-07-31 16:24:00-04:00,PBYI,neutral
985290.0,Puma Biotech Shares Up 8% In Pre-Market Following FDA Approval Of NERLYNX On Monday,2017-07-18 08:44:00-04:00,PBYI,positive
985291.0,"Puma Biotech Shares Resume Trading, Now Up 10.34% After-Hours",2017-07-17 17:55:00-04:00,PBYI,positive
985292.0,Puma Biotech Shares Resume Trading At 5:55pm ET,2017-07-17 17:50:00-04:00,PBYI,positive
985293.0,Puma Biotech Reports FDA Approval Of NERLYNX For Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer,2017-07-17 17:37:00-04:00,PBYI,negative
985294.0,Traders Circulating Doc From FDA Suggesting Puma Biotech Received Approval For Its Breast Cancer Treatment NERLYNX,2017-07-17 16:36:00-04:00,PBYI,negative
985295.0,Puma Biotech Shares Halted News Pending,2017-07-17 15:41:00-04:00,PBYI,positive
985296.0,"Leerink Swann Reinstates Outperform on Puma Biotechnology, Announces $115.00",2017-07-10 07:29:00-04:00,PBYI,neutral
985297.0,"Puma Biotech Completes Targeted Enrollment In Neratinib Phase III Trial, Expects Primary Analysis Available First Half 2018",2017-07-06 16:16:00-04:00,PBYI,neutral
985298.0,"Jefferies Health Care Conference Continues Today, Presenters Include Teva, WAVE Life Sciences, Envision Healthcare, NantKwest, Ignyta, Puma Biotech, and Kite Pharma",2017-06-07 08:23:00-04:00,PBYI,positive
985299.0,13G Filing Shows Partner Fund Reporting 8% Stake In Puma Biotech,2017-06-05 16:09:00-04:00,PBYI,neutral
985300.0,Cowen & Co. Upgrades Puma Biotechnology to Outperform,2017-05-25 07:32:00-04:00,PBYI,neutral
985301.0,Puma Biotech Shares Tick Slightly Higher Over Last Few Mins as Stifel Raises Price Target to New Street High at $105,2017-05-24 14:36:00-04:00,PBYI,positive
985302.0,"Puma Biotech Shares Resume Trade, Now Up 22-23%",2017-05-24 13:50:00-04:00,PBYI,positive
985303.0,Puma Biotech Shares to Resume Trade at 1:50 p.m. EDT,2017-05-24 13:34:00-04:00,PBYI,positive
985304.0,Puma Release Confirms Co.'s Neratinib Received FDA Panel Support,2017-05-24 13:29:00-04:00,PBYI,positive
985305.0,"Adam Feuerstein Tweets: Congrats to those who supported $PBYI & neratinib's approval in extended adjuvant breast. You were right. 

I did not and I was wrong.",2017-05-24 12:01:00-04:00,PBYI,positive
985306.0,CNBC's Meg Tirrell Tweets '$PBYI vote - risk/ben support treatment? Yes: 12 No: 4 Abstain: 0',2017-05-24 11:35:00-04:00,PBYI,positive
985307.0,CNBC's Meg Tirrell Tweets 'Another FDA panel member weighing in on concerns about broadness of $PBYI indication before vote',2017-05-24 11:32:00-04:00,PBYI,neutral
985308.0,Adam Feuerstein Tweets: $PBYI panel moving to discussion and voting. Live blog here —> thestreet.com/story/14146508,2017-05-24 11:26:00-04:00,PBYI,neutral
985309.0,"Adam Feuerestein Tweets: $PBYI panel break. Some more pointed concerns at end of Q&A but still going company's way, overall.",2017-05-24 10:29:00-04:00,PBYI,neutral
985310.0,"TheStreet's Adam Feuerstein Tweets '$PBYI panel is sorta boring so far, which probably works in its favor.'",2017-05-24 09:56:00-04:00,PBYI,negative
985311.0,TheStreet's Adam Feuerstein Tweets '$PBYI presenting neratinib data at FDA panel. Follow here —>',2017-05-24 08:27:00-04:00,PBYI,neutral
985312.0,"Adam Feuerstein Tweets: Re: $PBYI FDA panel. I'm interested in hearing from expert Dr. Hal Burstein. In '15, he called neratinib ""awful."" thestreet.com/story/13170389…",2017-05-23 12:21:00-04:00,PBYI,positive
985313.0,"Puma Biotech Shares Resumed Following Third Circuit Breaker Halt, Now Up 38.7%",2017-05-22 10:30:00-04:00,PBYI,positive
985314.0,"Forbes Reporter Matthew Herper Tweets: ..the recommendation not to file and the multiple trial amendments could be a real problem. If  study became biased, that hurts $PBYI.",2017-05-22 10:23:00-04:00,PBYI,negative
985315.0,Puma Biotech Shares to Resume Trade at 10:27:11 a.m. EDT Following Third Circuit Breaker Halt,2017-05-22 10:23:00-04:00,PBYI,positive
985316.0,"Puma Biotech Shares Halted on a Circuit Breaker to the Downside, Still Up ~51.5% for Session",2017-05-22 10:23:00-04:00,PBYI,positive
985317.0,"Puma Biotech Shares Resume Trade, Ticks Slightly Lower, Now Up 79% for Session",2017-05-22 10:15:00-04:00,PBYI,positive
985318.0,Puma Biotech Shares to Resume Trade at 10:14:51 a.m. EDT,2017-05-22 10:12:00-04:00,PBYI,positive
985319.0,"Puma Biotech Shares Now Up 83.5%, Around $69.35 Level; Halted on Third Circuit Breaker",2017-05-22 10:10:00-04:00,PBYI,positive
985320.0,"TheStreet's Adam Feuerstein Tweets 'For $PBYI bears, this ? from FDA: ""totality of evidence of neratinib's efficacy data in context of other approvals in the adjuvant setting/""'",2017-05-22 10:04:00-04:00,PBYI,neutral
985321.0,"Puma Biotech Shares Resume, Continue Higher, Now Up 58%",2017-05-22 10:03:00-04:00,PBYI,positive
985322.0,"Adam Feuerstein Tweets: $PBYI FDA review of neratinib played straight. No ""OMG"" landmines. Efficacy supportive, safety a concern. This is win for bulls. On to Weds.",2017-05-22 10:00:00-04:00,PBYI,positive
985323.0,Puma Biotech Shares to Resume Trade Following Second Circuit Breaker at 10:03:03 a.m. EDT,2017-05-22 09:58:00-04:00,PBYI,positive
985324.0,"Puma Biotech Shares Resume, Now Up 45.5%; Halted on Second Circuit Breaker",2017-05-22 09:58:00-04:00,PBYI,positive
985325.0,"UPDATE: Puma Biotech Briefing Docs Show Study 3004 Met Prespecified Primary Efficacy Endpoint, Showed Statistically Significant Improvement of iDFS in Patients Treated with Neratinib vs Placebo",2017-05-22 09:57:00-04:00,PBYI,positive
985326.0,"Puma Biotech Ad. Comm. Documents Shows neratinib Performed Better Than Roche's trastuzumab In I-SPY2 Trial, Particularly In Subgroup Of Patients That Were HRc Negative",2017-05-22 09:57:00-04:00,PBYI,negative
985327.0,Puma Biotech Shares to Resume Trade at 9:57:33 a.m. EDT,2017-05-22 09:53:00-04:00,PBYI,positive
985328.0,"Puma Biotech Shares Spike Into Positive Territory, Now Up 9%; Halted on Circuit Breaker",2017-05-22 09:53:00-04:00,PBYI,positive
985329.0,Puma Biotech Shares Spiking Higher As Briefing Documents For Wed. Ad Comm. Meeting Are Published To FDA,2017-05-22 09:52:00-04:00,PBYI,positive
985330.0,"Bank Of America Health Care Conference Begins Today; Presenters Include Luminex, Acadia Healthcare, Express Scripts, Puma Biotech, Ultragenyx Pharma, Alexion, Medicines Co., Juno, TherapeuticsMD, & Seattle Genetics",2017-05-16 08:32:00-04:00,PBYI,positive
985331.0,Puma Biotech Reports Q1 Adj. EPS $(1.16) vs $(1.98) Est.,2017-05-10 16:26:00-04:00,PBYI,neutral
985332.0,Adam Feuerstein Tweets: $PBYI CEO Alan Auerbach can end speculation by filing 8-K declaring Puma has not received the FDA briefing book on neratinib.,2017-05-05 10:39:00-04:00,PBYI,neutral
985333.0,Adam Fuerstein Tweets: Shortened FDA Advisory Panel is Bad Omen for $PBYI Controversial Breast Cancer Drug,2017-04-18 13:34:00-04:00,PBYI,negative
985334.0,Puma Biotech Reports FDA Advisory Committee to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer,2017-04-17 08:06:00-04:00,PBYI,negative
985335.0,Caligor Opco To Support Puma Biotechnology Expanded Access Program For PB272 In U.S.,2017-04-12 10:32:00-04:00,PBYI,positive
985336.0,UPDATE: 95.4% Of Puma's ExteNET Patients Experienced A Form of Diarrhea Ranked From Level 1 To 4 Grade,2017-04-04 13:10:00-04:00,PBYI,neutral
985337.0,Puma Biotechnology Says 39.8% Of ExteNET Patients Experienced Grade 3 or Higher Diarrhea In HER2-Positive Early Stage Breast Cancer,2017-04-04 13:06:00-04:00,PBYI,negative
985338.0,"Adam Feuerstein Tweets: Hedge funds that own $PBYI are screaming at sell side analysts to defend the stock, per my sources.",2017-03-02 08:50:00-05:00,PBYI,negative
985339.0,Puma Biotechnology To Modify Summary Of Product Characteristics To Restrict Intended Population To Patients Initiating Treatment Within On Year After Completion Of Adjuvant trastuzumab Patients,2017-03-01 16:47:00-05:00,PBYI,negative
985340.0,Puma Biotechnology Reports Q4 Adj. EPS $(1.22) vs $(1.92) Est.,2017-03-01 16:21:00-05:00,PBYI,neutral
985341.0,"Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma",2017-02-15 10:29:00-05:00,PBYI,neutral
985342.0,Stifel Nicolaus Upgrades Puma Biotechnology to Buy,2016-09-21 07:31:00-04:00,PBYI,neutral
985343.0,Stifel Nicolaus Upgrades Puma Biotechnology to Buy,2016-09-21 07:30:00-04:00,PBYI,neutral
985344.0,"Credit Suisse Maintains Outperform on Puma Biotechnology, Lowers PT to $50.00",2016-03-29 04:40:00-04:00,PBYI,positive
985345.0,"RBC Capital Downgrades Puma Biotechnology to Sector Perform, Lowers PT to $36.00",2016-03-29 04:40:00-04:00,PBYI,negative
985346.0,"JP Morgan Maintains Overweight on Puma Biotechnology, Lowers PT to $89.00",2016-03-29 04:40:00-04:00,PBYI,negative
985347.0,"Citigroup Maintains Buy on Puma Biotechnology, Lowers PT to $88.00",2016-03-29 04:40:00-04:00,PBYI,negative
985348.0,"Earlier Credit Suisse Initiated Coverage on Puma Biotechnology at Outperform, Announces $69.00 PT",2016-02-11 16:53:00-05:00,PBYI,positive
985349.0,"Credit Suisse Initiates Coverage on Puma Biotechnology at Outperform, Announces $69.00 PT",2016-01-20 16:49:00-05:00,PBYI,positive
985350.0,Citigroup Upgrades Puma Biotechnology to Buy,2015-12-14 09:05:00-05:00,PBYI,neutral
985351.0,"JP Morgan Initiates Coverage on Puma Biotechnology at Overweight, Announces $122.00 PT",2015-08-27 07:40:00-04:00,PBYI,neutral
985352.0,Cowen & Company Downgrades Puma Biotechnology to Market Perform,2015-05-05 07:49:00-04:00,PBYI,neutral
985353.0,Puma Biotechnology Prices 1M Share Offering @$190/Share,2015-01-21 20:11:00-05:00,PBYI,positive
985354.0,Puma Biotechnology Reports Q3 EPS of $(0.84) vs $(1.21) Est,2014-11-10 16:21:00-05:00,PBYI,neutral
985355.0,Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated NSCLC at ESMO 2014,2014-09-29 06:10:00-04:00,PBYI,positive
985356.0,Puma Biotechnology Reports Q2 EPS of $(1.29) Which May Not Compare $(0.66) Est,2014-08-11 16:37:00-04:00,PBYI,neutral
985357.0,"CORRECTION: Citigroup Initiates Coverage on Puma Biotechnology at Buy, Announces $123.00 PT",2014-04-21 08:24:00-04:00,PBYI,neutral
985358.0,Puma Biotechnology to Hold Conference Call to Provide Update on PB272 Clinical Trials in Patients with HER2 Mutations ,2013-12-17 08:08:00-05:00,PBYI,neutral
985359.0,From Earlier: Cowen Initiated Coverage on Puma Biotech at Outperform,2012-11-13 13:13:00-05:00,PBYI,neutral
985360.0,Benzinga's Top Initiations,2012-11-13 07:30:00-05:00,PBYI,positive
985361.0,Puma Biotechnology Closes $138 Million Public Offering of Common Stock  ,2012-10-24 14:07:00-04:00,PBYI,neutral
985362.0,Puma Biotech Closes $138M Offering of Stock; 8.63M Shares at $16,2012-10-24 14:04:00-04:00,PBYI,positive
985363.0,"Puma Biotechnology Announces Underwriters' Full Exercise of Overallotment Option, Increasing Total Offering Size to $138 Million ",2012-10-22 08:33:00-04:00,PBYI,neutral
985364.0,"Stifel Nicolaus Initiates Coverage on Puma Biotechnology at Buy, Announces PT of $19",2012-08-24 08:40:00-04:00,PBYI,neutral
